🪙The 2026 Tech Wealth Trilogy: Dell × PANW × MRNA

🐯 Hello Tigers!

The 2026 U.S. stock market has delivered a script beyond imagination. One company powers the AI server boom, another guards the gates of cybersecurity, and a third is pushing personalized mRNA cancer therapy into a new era.

On September 1, $Dell Technologies Inc.(DELL)$ and $Palo Alto Networks(PANW)$ reported their latest quarterly results, while $Moderna, Inc.(MRNA)$ continued to draw investor attention after its August 19 Phase 3 cancer-vaccine announcement.

Three stocks, three sectors, one shared logic: technological revolution is reshaping commercial value at unprecedented speed. Let's break it down. 🔍

01🏭 Dell: The AI Infrastructure "Money Printer" 🐯

⚡ Blowout Earnings: Across-the-Board Beat

📊 Revenue: $47B, +58% YoY, all-time high (est. $44.9B)

💰 Non-GAAP EPS: $7.04, +203% YoY (est. $4.91)

🖥️ AI Server Revenue: $16.4B, +100% YoY (est. ~$16B)

📦 New AI Orders: $60.9B, quarterly record

🔥 $95B Backlog: Demand Can't Be Contained

The AI server backlog reached a record $95 billion, up from $51.3 billion in the previous quarter. That's a $43.7B surge in a single quarter.

Over the past 12 months, $Dell Technologies Inc.(DELL)$ converted approximately $131.7B into AI server orders. Its AI Factory customer base has now surpassed 6,500, with around 3,300 customers added in just the last three quarters.

Jeff Clarke summed up the supply problem bluntly: “The constraints remain the same. DRAM, DRAM, DRAM followed by NAND, NAND, NAND.” 🔥

The bottleneck isn't demand — it's increasingly the availability of memory and other components.

📈 Guidance Raised Again: AI Outlook Jumps

🎯 FY27 Revenue Guidance: Raised to $192B (+69% YoY) from $167B

🖥️ AI Server Revenue Guidance: Raised to $74B from $60B

💵 Non-GAAP EPS Guidance: $25.50 (+148% YoY)

$Dell Technologies Inc.(DELL)$ raised its FY27 revenue outlook by $25B in a single update, while lifting its AI-server revenue forecast by $14B — a sharp upward revision that reflects how quickly AI infrastructure demand has accelerated.

Analysts entered earnings broadly positive on Dell. Wells Fargo carried a $545 target with an Overweight rating, while Goldman Sachs had a $510 target with a Buy rating. Those targets could be revised further following Dell's much stronger-than-expected FY27 outlook.

02🛡️ Palo Alto Networks: The AI Security "Gatekeeper" 🐯

📊 Q4 FY26: Strong Beat, But FY27 Growth Normalizes

The results were strong, but the valuation debate now shifts toward the pace of growth normalization. $Palo Alto Networks(PANW)$ expects FY27 revenue to grow 23–24% and NGS ARR to rise 22–23%, slower than Q4's headline growth rates even as near-term guidance remains robust.

📊 Q4 Revenue: $3.41B, +34% YoY (beat by 1.8%)

💰 Non-GAAP EPS: $1.02, +7% YoY (beat by 4.1%)

🔒 NGS ARR: $9.1B, +63% YoY

📋 RPO: $21.2B, +34% YoY

"The latest advancements in AI are elevating cybersecurity to the top of the CIO priority list..." — Nikesh Arora, CEO

⚠️ "Sweet Poison": Growth Slowdown Triggers Valuation Reset

📉 FY27 Revenue Growth Guidance: +23-24% (vs Q4's 34%)

📉 FY27 NGS ARR Growth Guidance: +22-23% (vs Q4's 63%)

⚠️ Valuation remains demanding: At around $362 per share, $Palo Alto Networks(PANW)$ trades at roughly 87x the midpoint of management's FY27 non-GAAP EPS guidance. With full-year revenue growth expected to normalize toward 23–24%, the valuation leaves relatively little room for execution disappointments.

The key issue for investors is whether Palo Alto Networks can sustain its valuation as revenue growth is expected to moderate to 23%-24% in FY27.

03🧬 Moderna: The mRNA "Wall-Breaker" 🐯

🔬 Historic Breakthrough: First mRNA Cancer Vaccine Phase 3 Success

On Aug 19, $Moderna, Inc.(MRNA)$ and $Merck(MRK)$ announced that their personalized mRNA cancer vaccine intismeran autogene (V940/mRNA-4157) combined with Keytruda met both primary endpoints (RFS and DMFS) in the Phase 3 INTerpath-001 trial. 🎯

Phase 3 INTerpath-001

• Primary endpoint: RFS met

• Key secondary endpoint: DMFS met

• 1,137 patients with resected Stage IIB-IV melanoma

Phase 2b KEYNOTE-942 — 5-Year Follow-Up

• Risk of recurrence or death reduced by 49% (HR=0.51)

• 5-year overall survival: 92.2% vs. 71.3% with Keytruda alone

🏆 Three "Firsts": First positive Phase 3 readout for an individualized neoantigen therapy; first positive Phase 3 readout for an mRNA-based cancer therapy; and the first Phase 3 study to demonstrate a clinically meaningful improvement over Keytruda alone in this adjuvant melanoma setting.

"For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality.”" — Stéphane Bancel, Moderna CEO

🎯 Analysts Pivot

📊 Bank of America: Underperform → Neutral, target $40 → $170
📈 Argus Research: Upgraded to Buy, target $180
💰 Goldman Sachs: Maintained Neutral, target $67 → $120
🔬 Wolfe Research: Underperform → Peer Perform, estimated $9.2B in unadjusted peak sales across four indications

📋 Consensus: Hold, avg target $110.35

The market remains sharply divided: bulls argue that the value of $Moderna, Inc.(MRNA)$'s mRNA oncology platform is still not fully reflected in the stock, while bears point to personalized manufacturing complexity, an approximately six-week production timeline in clinical studies, uncertain commercial pricing and the fact that regulatory approval is still pending.

Still, the Phase 3 success is widely viewed as a major milestone for personalized cancer therapy and mRNA technology.

🐯 Three Threads, One Era

🖥️ $Dell Technologies Inc.(DELL)$ (more than +230% YTD through Sept. 1) — AI hardware infrastructure beneficiary. $95B backlog represents the true depth of global AI compute demand. Bottleneck is DRAM supply, not demand.

🛡️ $Palo Alto Networks(PANW)$ (~+96% YTD) — AI security gatekeeper. The 113% April-to-June surge reflects the necessity of security spending as AI expands the attack surface. But slowing growth reminds markets: high valuations need sustained high growth.

🧬 $Moderna, Inc.(MRNA)$ (+177% on August 19, 2026 one-day) — mRNA technology wall-breaker. Phase 3 cancer vaccine success marks a narrative shift from COVID dependency to oncology platform. Scientific breakthroughs are translating into market value at unprecedented speed.

🐯 Three threads, one underlying logic: technological change is reshaping where investors see future value. AI infrastructure provides the compute, cybersecurity protects the expanding digital attack surface, and personalized medicine is opening an entirely new frontier in healthcare. Different industries — but the same market question: how quickly can technological breakthroughs translate into durable commercial value?

Investing is a long journey. Knowing when to move matters — and so does knowing when to recharge.

Markets may not slow down, but you can. Whether it’s a quick break between trading sessions or a long journey, staying comfortable helps you reset for what comes next. The new Night Trading Memory Foam Pillow features 360° ergonomic support and slow-rebound memory foam that gently conforms to your neck, plus a roll-up design that makes it easy to bring wherever you go.

https://ttm.financial/J/redeemGift?goodID=100540&type=delivery

Redeem the new Night Trading Memory Foam Pillow in Tiger Coins Mall, and stay supported for the journey ahead.